Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) Return on equity
Eli Lilly and Company's return on equity over the twelve months to 30 June 2026 was 102.3%, up 1.1 percentage points from fiscal 2025 (101.2%). Over the past ten years it has ranged from −1.59% (fiscal 2017) to 145.3% (fiscal 2020); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 101.2% | 16.90 |
| FY2024 | 84.3% | 35.83 |
| FY2023 | 48.4% | (14.24) |
| FY2022 | 62.7% | (11.85) |
| FY2021 | 74.5% | (70.80) |
| FY2020 | 145.3% | 23.06 |
| FY2019 | 122.3% | 93.63 |
| FY2018 | 28.6% | 30.22 |
| FY2017 | −1.59% | (20.69) |
| FY2016 | 19.1% | 3.03 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LLY Eli Lilly and Company | 102.3% |
| AMGN Amgen Inc. compare | 91.5% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. compare | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement